[The efficacy and safety of bortezomib, pomalidomide and dexamethasone regimen in the treatment of relapsed/refractory multiple myeloma]

Zhonghua Xue Ye Xue Za Zhi. 2023 Jul 14;44(7):602-605. doi: 10.3760/cma.j.issn.0253-2727.2023.07.016.

[Article in Chinese]

Authors

J Wang¹, H Xu¹, X X Chu², W Wang¹

Affiliations

¹ Hematology Department, The Affiliated Hospital of Qingdao University, Qingdao 266000, China.
² Hematology Department, Yantai Yuhuangding Hospital, Yantai 264000, China.

PMID: 37749045
PMCID: PMC10509612
DOI: 10.3760/cma.j.issn.0253-2727.2023.07.016

No abstract available

MeSH terms

Bortezomib / therapeutic use
Dexamethasone / therapeutic use
Humans
Multiple Myeloma* / drug therapy
Thalidomide / therapeutic use

Substances

Bortezomib
pomalidomide
Thalidomide
Dexamethasone